FDA Faces Backlash On Drug Compounding Limits
The U.S. Food and Drug Administration is facing strong pressure from a variety of companies and trade groups to dial back proposed restrictions on interstate shipments of compounded drugs, newly released...To view the full article, register now.
Already a subscriber? Click here to view full article